+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

European Genomic Biomarker Market 2019-2025

  • PDF Icon


  • January 2020
  • Region: Europe
  • Orion Market Research Private Limited
  • ID: 4988041
UP TO OFF until Dec 31st 2022
European Genomic Biomarker Market Size, Share & Trends Analysis Report, By Application (Oncology, Cardiology, Neurology, and Others), By End-User (Hospitals and Diagnostic & Research Laboratories), and Forecast 2019-2025.

The European genomics biomarker market is estimated to grow significantly at a CAGR of more than 14% during the forecast period. Factors that are contributing significantly to the market growth include the presence of a well-developed healthcare sector and considerably high healthcare expenditure and infrastructure in its economies such as Germany, UK, France, and others. Other factors contributing to the European genomics biomarker market include the rising prevalence of chronic diseases such as heart disease, cancer, diabetes, stroke, and arthritis. Unhealthy lifestyle such as smoking, consumption of drugs and alcohol in European countries are the major factors for increasing cancer incidences among men and women. Government initiatives, programs, and funding related to increasing awareness of cancer are also contributing to the growth of the market in the region.

The European genomic biomarker market is segmented on the basis of application and end-user. On the basis of application, the market is segmented into oncology, cardiology, neurology, and others. There is a huge scope for the market in the oncology segment due to the increasing prevalence of cancer. On the basis of end-user, the market is segmented into hospitals and diagnostic. Further, the report covers the country-level analysis of the genomics biomarker market in Europe. The major economies covered in the report include UK, Germany, Italy, Spain, France, and the Rest of Europe. The rest of Europe is estimated to hold a significant share in the market owing to the increasing healthcare spending in countries such as the Netherlands and Poland. As a result, it is primarily contributing to the adoption of advanced biomarkers for screening and detection of disease and thereby enabling the demand for genomic biomarkers. Moreover, Germany, UK, and Spain are estimated to grow at a considerable CAGR during the forecast period. The significant prevalence of CVD and cancer is expected to propel the adoption of the genomic biomarker in these countries.

Some of the major players in the European genomic biomarker market include F. Hoffmann-La Roche Ltd., Evotec AG, Becton Dickinson and Co., Qiagen NV, Novartis AG, and others. These companies are launching innovative products in the market, in order to meet the increasing demand for an effective diagnostic biomarker for cancer and cardiovascular diseases. Furthermore, the market players are adopting various strategies, in order to sustain in the competitive market, which includes partnership and collaboration, investments in R&D, and merger and acquisition. For instance, in April 2018, BioMérieux S.A. completed its acquisition of Astute Medical for around $90 million. Under this agreement, the company was given access to promising biomarkers in the product pipeline of Astute Medical.

Research Methodology

The market study of the European genomic biomarker market is incorporated by extensive primary and secondary research conducted by the research team. Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. The team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior and macro-economic factors.

Numbers extracted from Secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables the analyst to derive the closest possible figures without any major deviations in the actual number. the analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings authenticity to the reports.

Secondary Sources Include
  • Financial reports of companies involved in the market.
  • Whitepapers, research-papers, and news blogs.
  • Company websites and their product catalog.

The report is intended for healthcare companies, research institutes, hospitals, pharmaceutical, and biotechnology companies, potential investors and venture capitalists, government organizations, and other market participants for the overall market and competitive analysis. The report provides an in-depth analysis of the market size and future market opportunities. The report will serve as a source for 360-degree analysis of the market thoroughly delivering insights into the market for making better business decisions. The report will serve as a source for 360-degree analysis of the market thoroughly integrating different models.

Market Segmentation

1. European Genomic Biomarker Market Research and Analysis by Application
2. European Genomic Biomarker Market Research and Analysis by End-User

The Report Covers
  • Comprehensive research methodology of the European Genomic Biomarker Market.
  • This report also includes a detailed and extensive market overview with key analyst insights.
  • An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
  • Analysis of regional regulations and other government policies impacting the European Genomic Biomarker Market.
  • Insights about market determinants which are stimulating the European Genomic Biomarker Market.
  • Detailed and extensive market segments with regional distribution of forecasted revenues.
  • Extensive profiles and recent developments of market players.

Table of Contents

1. Report Summary
1.1. Research Methods and Tools
1.2. Market Breakdown
1.2.1. By Segments
1.2.2. By Geography
2. Market Overview and Insights
2.1. Scope of the Report
2.2. Analyst Insight & Current Market Trends
2.2.1. Key Findings
2.2.2. Recommendations
2.2.3. Conclusion
2.3. Rules & Regulations
3. Competitive Landscape
3.1. Company Share Analysis
3.2. Key Strategy Analysis
3.3. Key Company Analysis
3.3.1. Overview
3.3.2. Financial Analysis
3.3.3. SWOT Analysis
3.3.4. Recent Developments
4. Market Determinants
4.1. Motivators
4.2. Restraints
4.3. Opportunities
5. Market Segmentation
5.1. European Genomic Biomarker Market by Application
5.1.1. Oncology
5.1.2. Cardiology
5.1.3. Neurology
5.1.4. Others
5.2. European Genomic Biomarker Market by End-User
5.2.1. Hospitals
5.2.2. Diagnostic & Research Laboratories
6. Regional Analysis
6.1. UK
6.2. Germany
6.3. Italy
6.4. Spain
6.5. France
6.6. Rest of Europe
7. Company Profiles
7.1. Abcodia Ltd.
7.2. Acobiom SAS
7.3. Agendia N.V.
7.4. Agilent Technologies, Inc.
7.5. Avacta Group Plc
7.6. Bayer AG
7.7. BioMérieux S.A.
7.8. BioPorto Diagnostics A/S
7.9. Bio-Rad Laboratories, Inc.
7.10. DestiNA Genomics Ltd.
7.11. DNAVision SA
7.12. Eagle Genomics Ltd.
7.13. Epigenomics AG
7.14. Epistem Ltd
7.15. Eurofins Scientific SE
7.16. Evotec AG
7.17. F-Hoffman-La Roche Ltd.
7.18. IntegraGen SA
7.19. Merck KGaA
7.20. Novartis AG
7.21. Qiagen N.V.
7.22. Valirx PLC
7.23. The Almac Group

Companies Mentioned

A selection of companies mentioned in this report includes:

  • Abcodia Ltd.
  • Acobiom SAS
  • Agendia N.V.
  • Agilent Technologies, Inc.
  • Avacta Group Plc
  • Bayer AG
  • BioMérieux S.A.
  • BioPorto Diagnostics A/S
  • Bio-Rad Laboratories, Inc.
  • DestiNA Genomics Ltd.
  • DNAVision SA
  • Eagle Genomics Ltd.
  • Epigenomics AG
  • Epistem Ltd
  • Eurofins Scientific SE
  • Evotec AG
  • F-Hoffman-La Roche Ltd.
  • IntegraGen SA
  • Merck KGaA
  • Novartis AG
  • Qiagen N.V.
  • Valirx PLC
  • The Almac Group